Want to join the conversation?
$KORS FY15 10-K: Total OpEx increased 38.0% to $1,390.7MM compared to $1,007.9MM for FY14. OpEx as a percentage of total revenue increased to 31.8% as compared to 30.4% in FY14. KORS spent approx. $356MM on CapEx during FY15. The Company expects to spend approx. $400MM in CapEx during FY16.
$YHOO is reporting today after market close. Nobody cares about this stock.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.